Since past few decades, anti-cancer immunotherapies have experienced rapid clinical translation such as chimeric antigen receptor (CAR)-T cells therapy (use to enhance effective T-cells responses) targeting three major antigens i.e. human epidermal growth factor receptor-2 (HER2 or ERBB2), EGFRviii, and IL-12 receptor-α2 (IL-13Rα2) for brain tumors (77–79). Here, ERBB2 is linked to brain neoplasm.